香港股市 已收市
  • 恒指

    17,933.27
    -214.68 (-1.18%)
     
  • 國指

    6,114.40
    -81.50 (-1.32%)
     
  • 上證綜指

    3,088.37
    -20.54 (-0.66%)
     
  • 滬深300

    3,856.02
    -13.32 (-0.34%)
     
  • 美元

    7.8493
    +0.0010 (+0.01%)
     
  • 人民幣

    0.9074
    +0.0061 (+0.68%)
     
  • 道指

    29,590.41
    -486.27 (-1.62%)
     
  • 標普 500

    3,693.23
    -64.76 (-1.72%)
     
  • 納指

    10,867.93
    -198.88 (-1.80%)
     
  • 日圓

    0.0545
    -0.0004 (-0.66%)
     
  • 歐元

    7.6075
    -0.1113 (-1.44%)
     
  • 英鎊

    8.5140
    -0.3170 (-3.59%)
     
  • 紐約期油

    79.43
    -4.06 (-4.86%)
     
  • 金價

    1,651.70
    -29.40 (-1.75%)
     
  • Bitcoin

    18,924.88
    -237.70 (-1.24%)
     
  • CMC Crypto 200

    434.61
    -9.92 (-2.23%)
     

Evolent Expands Its Portfolio For Musculoskeletal Conditions With This Deal

·1 分鐘文章
  • Evolent Health Inc has agreed to acquire IPG, a technology and services company providing surgical management solutions for musculoskeletal conditions, from TPG Growth.

  • The deal value includes $375 million plus additional consideration of up to $87 million. It is expected to close in Q3 of 2022.

  • Upon close, the IPG team and platform will be integrated into New Century Health.

  • The deal expands Evolent's specialty focus to include surgical cost management focusing on musculoskeletal conditions, adding to its specialty portfolio of oncology, cardiology, and end-of-life care planning.

  • Evolent Health expects the transaction to be immediately accretive to adjusted EBITDA margins and cash flow.

  • It expects meaningful revenue cross-sell synergy opportunity with health plan and risk-bearing provider customers.

  • For 2022, IPG standalone revenues are expected to be $140 million, with an adjusted EBITDA of $25 million (approximately 18% margin) and annual sales growth of over 20%.

  • Evolent will fund $250 million of the purchase price in cash through a combination of $25 million cash on hand and proceeds from a new $225 million Five Year Senior Credit Facility provided by Ares Management.

  • Evolent ended the March quarter with a cash balance of $210.2 million.

  • Price Action: EVH shares closed at $30.88 on Tuesday.

View more earnings on EVH

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.